IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences (NASDAQ: IDYA) has announced the grant of non-qualified stock options to two newly hired employees. The Compensation Committee approved options to purchase 62,800 shares of common stock on January 30, 2025, under the company's 2023 Employment Inducement Incentive Award Plan.
The stock options were granted at an exercise price of $23.88 per share, matching IDEAYA's closing price on The Nasdaq Global Select Market on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, subject to continued employment.
IDEAYA Biosciences (NASDAQ: IDYA) ha annunciato il conferimento di opzioni su azioni non qualificate a due nuovi dipendenti. Il Comitato per la Retribuzione ha approvato opzioni per l'acquisto di 62.800 azioni di azioni ordinarie il 30 gennaio 2025, nell'ambito del piano di incentivazione per l'occupazione 2023 dell'azienda.
Le opzioni su azioni sono state concesse a un prezzo di esercizio di $23,88 per azione, corrispondente al prezzo di chiusura di IDEAYA sul mercato Nasdaq Global Select alla data del conferimento. Queste opzioni hanno una durata di 10 anni e si matureranno in un periodo di quattro anni, con il 25% che si matura dopo il primo anno e il restante 75% che si matura mensilmente nei successivi tre anni, soggetto a mantenimento dell'impiego.
IDEAYA Biosciences (NASDAQ: IDYA) ha anunciado la concesión de opciones sobre acciones no calificadas a dos nuevos empleados. El Comité de Compensación aprobó opciones para comprar 62,800 acciones de acciones ordinarias el 30 de enero de 2025, bajo el Plan de Incentivos por Empleo 2023 de la compañía.
Las opciones sobre acciones se otorgaron a un precio de ejercicio de $23.88 por acción, coincidiendo con el precio de cierre de IDEAYA en el mercado Nasdaq Global Select en la fecha de concesión. Estas opciones tienen un plazo de 10 años y se ejercerán durante cuatro años, con un 25% que se ejercerá después del primer año y el restante 75% que se ejercerá mensualmente durante los siguientes tres años, sujeto a la continuación del empleo.
IDEAYA Biosciences (NASDAQ: IDYA)는 두 명의 신규 직원에게 비자격 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 2023년 고용 유도 인센티브 상에 따라 62,800주의 보통주를 구매할 수 있는 옵션을 2025년 1월 30일에 승인했습니다.
주식 옵션은 주당 $23.88의 행사 가격으로 부여되었으며, 이는 부여일 기준 IDEAYA의 나스닥 글로벌 셀렉트 마켓에서의 종가와 일치합니다. 이 옵션은 10년의 기간을 가지며 4년에 걸쳐 분할적으로 부여됩니다. 첫 해에 25%가 부여되고, 나머지 75%는 다음 3년 동안 매달 부여되며, 지속적인 고용이 전제조건입니다.
IDEAYA Biosciences (NASDAQ: IDYA) a annoncé l'octroi d'options d'actions non qualifiées à deux nouveaux employés. Le Comité de Rémunération a approuvé des options d'achat de 62 800 actions de l'entreprise le 30 janvier 2025, dans le cadre de son Plan d'Incitatif à l'Emploi 2023.
Les options d'achat d'actions ont été accordées à un prix d'exercice de 23,88 $ par action, correspondant au prix de clôture d'IDEAYA sur le marché Nasdaq Global Select à la date d'octroi. Ces options ont une durée de 10 ans et seront acquises sur quatre ans, avec 25 % devenant acquis après la première année et les 75 % restants devenant acquis mensuellement au cours des trois années suivantes, sous réserve d'un emploi continu.
IDEAYA Biosciences (NASDAQ: IDYA) hat die Vergabe von nicht qualifizierten Aktienoptionen an zwei neu eingestellte Mitarbeiter bekannt gegeben. Der Vergütungsausschuss genehmigte Optionen zum Kauf von 62.800 Aktien am 30. Januar 2025 im Rahmen des Tarifplans für Beschäftigungsanreize 2023 des Unternehmens.
Die Aktienoptionen wurden zu einem Ausübungspreis von $23,88 pro Aktie gewährt, was dem Schlusskurs von IDEAYA am Nasdaq Global Select Market am Tag der Gewährung entspricht. Diese Optionen haben eine Laufzeit von 10 Jahren und werden über einen Zeitraum von vier Jahren ausgegeben, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % monatlich über die folgenden drei Jahre gewährt werden, abhängig von der fortgesetzten Beschäftigung.
- None.
- None.
The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302365097.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is the exercise price of IDYA's newly granted stock options on January 30, 2025?
How many shares of IDYA stock options were granted to new employees in January 2025?
What is the vesting schedule for IDYA's January 2025 employee stock options?
How long is the term of IDYA's January 2025 employee stock options?
